KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash from Financing Activities (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Cash from Financing Activities for 8 consecutive years, with -$4.6 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 14.78% to -$4.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$7.0 million through Dec 2025, down 213.37% year-over-year, with the annual reading at -$7.0 million for FY2025, 213.37% down from the prior year.
  • Cash from Financing Activities hit -$4.6 million in Q4 2025 for Castle Biosciences, down from -$919000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $10.6 million in Q1 2024 to a low of -$5.4 million in Q4 2024.
  • Historically, Cash from Financing Activities has averaged $190850.0 across 5 years, with a median of $176000.0 in 2021.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 695.24% in 2022 and later surged 1762.22% in 2024.
  • Year by year, Cash from Financing Activities stood at $126000.0 in 2021, then tumbled by 695.24% to -$750000.0 in 2022, then plummeted by 339.6% to -$3.3 million in 2023, then crashed by 63.33% to -$5.4 million in 2024, then increased by 14.78% to -$4.6 million in 2025.
  • Business Quant data shows Cash from Financing Activities for CSTL at -$4.6 million in Q4 2025, -$919000.0 in Q3 2025, and $101000.0 in Q2 2025.